WPRIM Management System> DCMS> Chinese Journal of Clinical Oncology> 2014> > 24

Volume: Issue: 24

1. Centralized cancer pain cognition situation in basic medical staff from China Page:1509—1511
2. Clinical analysis of standardized drug treatment of cancer pain at the pain clinic Page:1506—1508
3. Research progress of epigenetics therapy for lung cancer Page:1570—1572
4. Research advancement on BNIP3 in gastrointestinal cancer Page:1567—1569
5. Influencing factor of whole-body scan imaging on radioactive io-dine treatment for lung metastases of differentiated thyroid carci-noma Page:1558—1562
6. Therapeutic strategy to prevent the recurrence of esophageal carci-noma after radical resection Page:1553—1557
7. Research progress on the dual regulation of c-FLIP in apoptosis and proliferation and the relationship between c-FLIP and tumor prognosis, chemotherapy, and TRAIL treatment in cancers Page:1573—1576
8. Report and literature review of two cases of coma induced by beva-cizumab combined with chemotherapy Page:1563—1566
9. Reasonable naloxone administration in cancer pain management Page:1487—1491
10. Oncostatin M combined with dacarbazine inhibits proliferation of melanoma cell B16 Page:1540—1543
11. Relationship between EGFR mutation and pulmonary tuberculo-sis in lung adenocarcinoma patients Page:1535—1539
12. Relationship between human papillomavirus gene types and cervi-cal diseases Page:1531—1534
13. Survivin mRNA is suppressed in HepG2 cells after AFP gene silencing Page:1528—1530
14. Simvastatin inhibits expression of pluripotent markers Oct3/4, Nanog, and Sox-2 in human breast cancer MCF-7 Cells Page:1523—1527
15. Inhibition of the JNK pathway downregulates lung-resistance pro-tein and enhances the chemosensitivity of A549 cells to cisplatin Page:1518—1522
16. Application of pain assessment management informationization in cancer pain standardized demonstration ward Page:1512—1516
17. Opioid overdose in advanced cancer patients antagonized by nalox-one:a report of 15 cases Page:1502—1505
18. Pharmacological characteristics and clinical application of trans-dermal fentanyl in cancer pain management Page:1495—1497
19. Advances in the research of neurolytic celiac plexus block Page:1492—1494
20. Application of pain assessment tools in cancer pain patients Page:1482—1486
21. Clinicopathological features and prognostic factors of breast can-cer in women aged under 25 years:a report of 77 cases Page:1548—1552
22. Analysis of 7 578 malignant tumor cases in Kashga, Xinjiang Page:1544—1547
23. Advances in research on microRNA-21 in colorectal cancer Page:1616—1618
24. Advances in lymphoma maintenance therapy with rituximab Page:1612—1615
25. Correlation studies of VEGF-C/D and its receptor with lymph node metastasis in gastric cancer Page:1608—1611
26. Mesenchymal to epithelial transition in malignant mesenchymal tu-mors Page:1602—1607
27. Progression of immunomodulatory molecules in the change of can-cer chemotherapy sensitivity Page:1597—1601
28. Efficacy of recombinant human endostatin (Endostar) combined with chemotherapy for malignant pleural effusion in non-small cell lung cancer patients Page:1573—1576
29. Effect of excision extension of primary tumors on local control and survival of stage IV neuroblastoma Page:1568—1572
30. Expression and clinical significance of serum microRNA-100 in gastric cancer patients Page:1587—1590
31. Comparison of clinical study for thoracolaparoscopic esophagecto-my and open two-field lymph node dissection esophagectomy for stage middle esophageal carcinoma Page:1577—1581
32. Application of controlled low central venous pressure combined with hepatic blood occlusion in hepatectomy Page:1174—1177
33. Expression of neurokinin receptors and the effect of their antago-nists on human breast cancer Page:1167—1173
34. Analysis of factors influencing 18F-FDG metabolic parameters in PET/CT scan for lung cancer Page:1163—1166
35. Mechanisms of action, resistance, and countermeasures of targeted therapy in advanced renal cell carcinoma Page:1159—1162
36. Research progress on PD-1/PD-L1 inhibitors in tumor immuno-therapy Page:1178—1182

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.